Scientists make advances in stem-cell-based liver toxicity testing
This article was originally published in Scrip
A research project involving scientists in the UK and the US has produced liver cells from induced pluripotent stem cells (iPSC) for use in drug toxicity testing. One of the partners in the project, the MRC's Scottish Centre for Regenerative Medicine, is looking to set up a collaboration with researchers in China who recently achieved a similar success.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.